Literature DB >> 2427649

Isolation of variants of lymphocytopathic retroviruses from the peripheral blood and cerebrospinal fluid of patients with ARC or AIDS.

H Rübsamen-Waigmann, W B Becker, E B Helm, R Brodt, H Fischer, K Henco, H D Brede.   

Abstract

LAV/HTLV-III/AAV viruses were isolated from 20 German patients with ARC/AIDS in order to investigate strain variation. Virus was isolated from the peripheral blood and/or cerebrospinal fluid (CSF) in umbilical cord peripheral blood lymphocyte (PBL) cultures. Isolates were identified by their cytopathic effect (CPE), by reverse transcriptase assays on cell-free infected culture supernatant fluid (SNF), and one or more of the following: immunofluorescence assays on infected cells for viral antigen using HTLV-III reference sera, Western blot analysis of cell-free infected culture SNF, electron microscopy of infected cells, and Southern blot restriction analysis and specific HTLV-III probing of DNA extracted from infected cultured PBL. The isolates could be classified into three groups according to differences in growth rate and cytopathic effect: Most showed what was regarded as the typical CPE, while some either grew rapidly and induced a striking CPE and others grew slowly with minimal CPE. In one patient, virus producing typical CPE was isolated from the peripheral blood while the isolate from his filtered cell-free CSF produced atypical slow CPE, suggesting that antigenic variation may occur with persistent infection or that superinfection may occur. Southern blot DNA restriction analysis of the DNA of three selected isolates showed that two of the isolates were similar but that the restriction pattern of all three differed from patterns previously published. Our results supplement the accumulating evidence of genetic variation among LAV/HTLV-III strains. The extent of this variation needs to be evaluated for any effect on the sensitivity of diagnostic tests, on the strategy of vaccine development, on tissue tropism by altering the viral surface receptor-binding sites, and possibly on the development of specific chemotherapy.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 2427649     DOI: 10.1002/jmv.1890190406

Source DB:  PubMed          Journal:  J Med Virol        ISSN: 0146-6615            Impact factor:   2.327


  21 in total

1.  Markers for HIV-disease progression in untreated patients and patients receiving AZT: evaluation of viral activity, AZT resistance, serum cholesterol, beta 2-microglobulin, CD4+ cell counts, and HIV antigen.

Authors:  H Rübsamen-Waigmann; B Schröder; L Biesert; C D Bauermeister; H von Briesen; H Suhartono; F Zimmermann; H D Brede; A Regeniter; S Gerte
Journal:  Infection       Date:  1991       Impact factor: 3.553

2.  Human immunodeficiency virus (HIV)-positive sera obtained shortly after seroconversion neutralize autologous HIV type 1 isolates on primary macrophages but not on lymphocytes.

Authors:  H Ruppach; P Nara; I Raudonat; Z Elanjikal; H Rübsamen-Waigmann; U Dietrich
Journal:  J Virol       Date:  2000-06       Impact factor: 5.103

3.  Molecular cloning of two west African human immunodeficiency virus type 2 isolates that replicate well in macrophages: a Gambian isolate, from a patient with neurologic acquired immunodeficiency syndrome, and a highly divergent Ghanian isolate.

Authors:  H Kühnel; H von Briesen; U Dietrich; M Adamski; D Mix; L Biesert; R Kreutz; A Immelmann; K Henco; C Meichsner
Journal:  Proc Natl Acad Sci U S A       Date:  1989-04       Impact factor: 11.205

4.  Chronic HIV encephalitis--II. Clinical aspects.

Authors:  S Poser; W Lüer; D Eichenlaub; H D Pohle; T Weber; S Jürgens; K Felgenhauer
Journal:  Klin Wochenschr       Date:  1988-01-04

5.  Alpha interferon (2b) in combination with zidovudine for the treatment of presymptomatic feline leukemia virus-induced immunodeficiency syndrome.

Authors:  N S Zeidner; M H Myles; C K Mathiason-DuBard; M J Dreitz; J I Mullins; E A Hoover
Journal:  Antimicrob Agents Chemother       Date:  1990-09       Impact factor: 5.191

6.  Nonnucleoside reverse transcriptase inhibitors that potently and specifically block human immunodeficiency virus type 1 replication.

Authors:  D L Romero; M Busso; C K Tan; F Reusser; J R Palmer; S M Poppe; P A Aristoff; K M Downey; A G So; L Resnick
Journal:  Proc Natl Acad Sci U S A       Date:  1991-10-01       Impact factor: 11.205

7.  Activity of a novel quinoxaline derivative against human immunodeficiency virus type 1 reverse transcriptase and viral replication.

Authors:  J P Kleim; R Bender; U M Billhardt; C Meichsner; G Riess; M Rösner; I Winkler; A Paessens
Journal:  Antimicrob Agents Chemother       Date:  1993-08       Impact factor: 5.191

8.  Differences in cytopathogenicity and host cell range among infectious molecular clones of human immunodeficiency virus type 1 simultaneously isolated from an individual.

Authors:  K Sakai; S Dewhurst; X Y Ma; D J Volsky
Journal:  J Virol       Date:  1988-11       Impact factor: 5.103

9.  Immunoglobulin class- and subclass-specific HIV antibody detection in serum and CSF specimens by ELISA and Western blot.

Authors:  K Mergener; W Enzensberger; H Rübsamen-Waigmann; H von Briesen; H W Doerr
Journal:  Infection       Date:  1987       Impact factor: 3.553

10.  Polo-like kinase, a novel marker for cellular proliferation.

Authors:  J Yuan; A Hörlin; B Hock; H J Stutte; H Rübsamen-Waigmann; K Strebhardt
Journal:  Am J Pathol       Date:  1997-04       Impact factor: 4.307

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.